Coronavirus Disease 2019 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies
Author(s) -
Robby Nieuwlaat,
Lawrence Mbuagbaw,
Dominik Mertz,
Lori L. Burrows,
Dawn M. E. Bowdish,
Lorenzo Moja,
Gerard D. Wright,
Holger J. Schünemann
Publication year - 2020
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa773
Subject(s) - pandemic , covid-19 , medicine , intensive care medicine , coronavirus , disease , antibiotic resistance , risk analysis (engineering) , infectious disease (medical specialty) , virology , outbreak , antibiotics , pathology , microbiology and biotechnology , biology
The coronavirus disease 2019 (COVID-19) pandemic and antimicrobial resistance (AMR) are parallel and interacting health emergencies that provide the opportunity for mutual learning. As their measures and consequences are comparable, the COVID-19 pandemic helps to illustrate the potential long-term impact of AMR, which is less acute but not less crucial. They may also impact each other as there is a push to use existing antimicrobials to treat critically ill COVID-19 patients in the absence of specific treatments. Attempts to manage the spread of COVID-19 may also lead to a slowdown in AMR. Understanding how COVID-19 affects AMR trends and what we can expect if these trends remain the same or worsen will help us to plan the next steps for tackling AMR. Researchers should start collecting data to measure the impact of current COVID-19 policies and programs on AMR.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom